A combination of low cancer event rates, poor diagnostic consistency and short follow‐up times of studies included in quantitative reviews assessing cancer risk in SGLT‐2 inhibitor users thus far have made it difficult for clinicians to draw confident conclusions on potentially relevant implications of this data in practice. The gene discussed is SLC5A2; the disease is cancer.